Kodiak Sciences Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Kodiak Sciences Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($229.97M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($176.21M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($260.49M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($333.82M) | Mar 27, 2025 |
| FY2021 | Dec 31, 2021 | ($93.17M) | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | ($67.53M) | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | ($55.85M) | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | ($50.45M) | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | ($46.58M) | Mar 1, 2022 |
| FY2021 | Sep 30, 2020 | ($36.12M) | Mar 1, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($234.39M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($186.85M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($277.32M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($341.38M) | Mar 27, 2025 |
| FY2021 | Dec 31, 2021 | ($93.05M) | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | ($67.54M) | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | ($55.91M) | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | ($50.56M) | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | ($46.84M) | Mar 1, 2022 |
| FY2021 | Sep 30, 2020 | ($36.66M) | Mar 1, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $182.37M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $126.10M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $206.30M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $267.59M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $217.34M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $107.39M | Mar 28, 2023 |
| FY2021 | Dec 31, 2019 | $37.51M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $18.79M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $22.02M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $14.05M | Mar 27, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($136.01M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($117.32M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($154.18M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($206.46M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | ($182.27M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | ($83.43M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2019 | ($39.15M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($29.03M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($17.66M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | ($16.05M) | Mar 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $506.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $375.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $41.35M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $37.02M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $17.03M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $3.81M | Mar 28, 2023 |
| FY2021 | Dec 31, 2019 | $437.0K | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $78.0K | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $209.0K | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $771.0K | Mar 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $351.53M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $335.58M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $479.37M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $666.63M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $904.22M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $1.07B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $358.87M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $92.19M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $3.24M | Mar 27, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $194.15M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $185.29M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $213.59M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $230.46M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $240.90M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $206.60M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $13.51M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $5.36M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $21.97M | Mar 27, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $157.38M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $150.29M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $265.78M | Mar 31, 2026 |
| FY2025 | Dec 31, 2022 | $436.17M | Mar 31, 2026 |
| FY2024 | Dec 31, 2021 | $663.32M | Mar 27, 2025 |
| FY2023 | Dec 31, 2020 | $860.75M | Mar 28, 2024 |
| FY2022 | Dec 31, 2019 | $345.36M | Mar 28, 2023 |
| FY2021 | Dec 31, 2018 | $86.83M | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | ($68.74M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | ($41.08M) | Mar 16, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.56B) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($1.33B) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($1.15B) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($892.04M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($558.22M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($291.23M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($158.13M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($110.77M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($69.32M) | Mar 27, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $209.86M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $168.07M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $285.51M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $190.43M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $731.51M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $944.40M | Mar 28, 2023 |
| FY2021 | Dec 31, 2019 | $211.80M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $88.25M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $1.40M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $9.62M | Mar 27, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | (4) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | (6) | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | (5) | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Mar 28, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | (4) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | (6) | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | (5) | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Mar 28, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 61.76M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 52.73M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 52.51M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 52.33M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 51.83M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 51.11M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 44.41M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 36.83M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 7.94M | Mar 27, 2019 |